Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EPS (Weighted Average and Diluted) (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.45 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) fell 55.17% year-over-year to -$0.45, compared with a TTM value of $0.15 through Dec 2025, up 109.43%, and an annual FY2025 reading of $0.2, up 112.5% over the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.45 in Q4 2025 for Apellis Pharmaceuticals, down from $1.67 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $1.67 in Q3 2025, with the low at -$2.72 in Q2 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.02 (2023), compared with a mean of -$0.98.
  • The sharpest move saw EPS (Weighted Average and Diluted) crashed 195.27% in 2021, then skyrocketed 463.04% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$1.53 in 2021, then increased by 1.96% to -$1.5 in 2022, then soared by 52.0% to -$0.72 in 2023, then skyrocketed by 59.72% to -$0.29 in 2024, then plummeted by 55.17% to -$0.45 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.45, $1.67, and -$0.33 for Q4 2025, Q3 2025, and Q2 2025 respectively.